



In the United States Patent and Trademark Office

In Re: Sanders, Ira et al
SN: 10/535,504
Filed: 05/18/2005
For: Treatment of Mammalian etc.

Group Art Unit: 1645
Examiner: Swartz, Rodney

Mail Stop Fee Amendments
Hon Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

I, Omri M. Behr hereby certify that this correspondence is being filed electronically via first class mail addressed to Commissioner for Patents PO Box 1450, Alexandria VA 22313-1450 on December 11th 2007

(Date of Deposit)


Omri M. Behr

date: 12.11.07

Information Disclosure Statement under 37 CFR 1.97(e)(10)

In consequence of a search report originally received from the European Patent Office dated November 23rd 2007, applicant files herewith a copy of said report, a copy (2 pages Of PTO/SB/08 A and B) and copies of all of the document cited in said search report together with the appropriate fee of \$180.

The citation of **Sanders** (WO 02.00172 A2) has caused applicant to restrict the scope of the claims to exclude neurotoxins related to C. Tetani so no further comment is required.

Aoki (US 2002 /082197 A1) while disclosing therapeutic use of BoNT at paragraph 0015, does not teach the use of such neurotoxin for blocking or reducing physiological reaction in a patient to the interaction of IgE antibodies present in said patient upon contact with the corresponding antigen.


Borodic (US 6429189B1) does not make use of the neurotoxins that are disclosed and claimed in the present application except in one instance. However in that instance the experiment, as are the claims, is directed to inflammation and pain, not allergy in the manner disclosed and claimed in the present application

Elan (WO00/15245) discloses various uses for BoNT in various forms but does not appear to recognize the antiallergenic properties or that the autonomic nervous system plays a central role in allergic disorders. The disclosure appears to be directed to methods of preparing stable BoNT formulations and testing them.

Rohrbach (Medline NLM 11713429) is directed to a form of rhinorrhea which is not allergy connected. In deed it is a repetition of earlier work reported by applicant.

Unal (Medline NLM 14710908) is not citable against the present application date as its publication date is one month after the PCT priority date and over one year after the provisional application from which the present application derives.

Respectfully submitted,



Omri M. Behr

Reg: 22940, Cust #:47375

The Behr Office
325 Pierson Avenue
Edison NJ 08837-3123
Ph: 908 202 5806
Fx: 732 494 6258
Email: bepat@prodigy.net